WHO Warns About Fake Diabetes and Weight-Loss Drugs
The World Health Organization has issued a warning about false semaglutides used in diabetes and weight-loss drugs, detected in Brazil, the UK, and the USA. Semaglutide is the active ingredient in Ozempic and Wegovy. Falsified products may cause health complications due to unmanaged blood glucose levels or weight.
The World Health Organization (WHO) has issued a warning about falsified semaglutides used in diabetes and weight-loss drugs.
These fake products have been detected in three altered batches in Brazil, the UK, and the United States.
Semaglutide is the active ingredient in Novo Nordisk's diabetes drug, Ozempic, and weight-loss treatment, Wegovy.
The WHO has been monitoring an increase in fake semaglutide products in these countries since 2022.
This warning marks the agency's first official notice after confirming some reports.
Falsified products could be harmful, potentially resulting in health complications from unmanaged blood glucose levels or weight.
These fake products have been detected in three altered batches in Brazil, the UK, and the United States.
Semaglutide is the active ingredient in Novo Nordisk's diabetes drug, Ozempic, and weight-loss treatment, Wegovy.
The WHO has been monitoring an increase in fake semaglutide products in these countries since 2022.
This warning marks the agency's first official notice after confirming some reports.
Falsified products could be harmful, potentially resulting in health complications from unmanaged blood glucose levels or weight.